Social Cognition in Huntington's Disease: Cognitive Study and Functional and Morphological Imaging

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02550275

Acronym

COSIMH

Enrollment

Registered

2015-09-15

Start date

2015-01-31

Completion date

2017-03-31

Last updated

2020-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huntington's Disease

Brief summary

Huntington's disease is a rare genetic neurodegenerative disease. It is accompanied by movement disorders, cognitive and behavioral. The social behavior of patients are changed, affecting interpersonal relationships. Patients with Huntington's disease are described as self-centered, lacking sympathy and empathy and mentally inflexible. These behavioral problems can be a major source of anxiety for patients and their families. These disorders also have a negative impact cognitive and motor symptoms as well as the functional abilities and the quality of life of patients and their entourage. Authors have suggested that these problems could be related inter alia to social cognition disorders. This concept refers to a set of skills and emotional and social experiences that regulate relations between individuals and can explain the behavior of individuals and groups. The objective is to evaluate disorders of social cognition, which may account for behavioral changes in Huntington's disease.

Interventions

BEHAVIORALneuropsychological test

RADIATIONMRI

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

For all particpipants * Patient gave its written consent * between 20 and 70 years * School level : at least 7 years * native language: french For presymptomatic patient * Huntington's disease diagnosed with abnormal number of CAG repeats: 36 \< nucleotide expansion (CAG) * Unified Huntington Disease Rating Scale moteur ≤ 5 For symptomatic patient * Huntington's disease diagnosed with abnormal number of CAG repeats: 36 \< nucleotide expansion (CAG) * Unified Huntington Disease Rating Scale moteur \> 5

Exclusion criteria

* No national health insurance affiliation * Being under guardianship * Meeting brain MRI

Design outcomes

Primary

Measure	Time frame
the achievement of social cognition process in Huntington's disease using the total score of the scale 15-TOM	3 months after inclusion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026